Skip to main content

Table 1 Study characteristics of included studies

From: Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

Study Study design Participants Sample size (M/F) Intervention/control a Outcomes
Yao et al. Cohort study 45–75 years old (mean: 63); all patients with SqCC; stage III B 20 cases/stage IV 51 cases 71 (69/2);
CIV: 48 (47/1);
IIV: 23 (22/1)
CIV: Endostar by infusion pump (15 mg/d, 11 ml/h) from day 0 to 8, combined with GP chemotherapy (gemcitabine and cisplatin);
IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 0 to 13, combined with GP chemotherapy (gemcitabine and cisplatin)
Efficacy: OS, PFS, ORR, DCR; safety: leukopenia, neutropenia, thrombocytopenia, anemia, hyponatremia, Transaminase elevation, laryngeal hemorrhage, hypertension, fatigue, nausea & vomiting, constipation, diarrhea, papule, purulent herpes, fever, thromboembolism
Li et al. Cohort study 41–70 years old; all patients with NSCLC; stage III B 34 cases/stage IV 82 cases 116 (77/39);
CIV: 58 (40/18);
IIV: 58 (37/21)
CIV: Endostar by mini-osmotic pump (210 mg, 5 ml/h) from day 1 to 10, combined with docetaxel, gemcitabine, pemetrexed, cisplatin, nedaplatin, etc.;
IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 1 to 14, combined with docetaxel, gemcitabine, pemetrexed, cisplatin, nedaplatin, etc.
Efficacy: OS, PFS, ORR, DCR;
safety: neutropenia, anemia, thrombocytopenia, hemorrhage, nausea & vomiting, mucositis, constipation, diarrhea, transaminase elevation, total bilirubin elevation, blood creatinine elevation, fever, rash, fatigue, pain, allergy, peripheral neurotoxicity, alopecia, arrhythmia
Cheng et al. Cohort study 33–78 years old (mean: 59.5); SqCC 21 cases/ADC: 36 cases/other types 12 cases; stage III 7 cases/stage IV 54 cases/postoperative recurrence 8 cases 69 (50/19);
CIV: 20 (13/7);
IIV: 49 (37/12)
CIV: Endostar by mini-osmotic pump (105 mg/m2, 10 ml/h) from day 1 to 5, combined with first-line chemotherapy (gemcitabine and platinum, pemetrexed and platinum, or paclitaxel and platinum);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with first-line chemotherapy (gemcitabine and platinum, pemetrexed and platinum, or paclitaxel and platinum)
Efficacy: PFS, ORR, DCR;
safety: Neutropenia, anemia, thrombocytopenia, arrhythmia, myocardial ischemia, neurotoxicity, rash, transaminase elevation, vomiting, infection, nausea, deep vein thrombosis, hemorrhage
Zhu et al. Cohort study 33–75 years old (median: 58); SqCC 16 cases/ADC 45 cases/other types 3 cases; all patients with advanced NSCLC 64 (46/18);
C: 33;
IIV: 31
CIV: Endostar by infusion pump (210 mg, 3 ml/h) from day 1 to 7, combined with AP chemotherapy (pemetrexed and cisplatin) or TP (paclitaxel and cisplatin);
IIV: Endostar by intravenous infusion (15 mg/d, 4 h/d) from day 1 to 14, combined with AP chemotherapy (pemetrexed and cisplatin) or TP (paclitaxel and cisplatin)
Efficacy: PFS, ORR, DCR;
safety: myelosuppression, liver dysfunction, gastrointestinal reaction, cardiovascular toxicity, peripheral neurotoxicity, hemoptysis
Pang et al. RCT 41–76 years old (mean: 61); SqCC 33 cases/ADC 45 cases/AdSqCC 3 cases/LCC 3 cases; stage III B 32 cases/stage IV 52 cases 84 (48/36);
CIV: 42 (23/19);
IIV: 42 (25/17)
CIV: Endostar by infusion pump (7.5 mg/m2/d, 5 ml/h) from day 1 to 7, combined with GP chemotherapy (gemcitabine and cisplatin);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin)
Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, liver dysfunction, neurotoxicity, fatigue, diarrhea
Wen and Chen RCT 24–76 years old (median: 58); SqCC 39 cases/ADC 28 cases/AdSqCC 4 cases; stage III B 48 cases/stage IV 23 cases; initial treatment 46 cases/retreatment 25 cases 71 (45/26);
CIV: 37;
IIV: 34
CIV: Endostar by infusion pump (7.5 mg/m2/d, 10 ml/h) from day 1 to 14, combined with TC chemotherapy (paclitaxel and carboplatin);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with TC chemotherapy (paclitaxel and carboplatin)
Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, alopecia, muscle & joint soreness
Kahaerjiang et al. NRCT 34–75 years old (median: 51.5); SqCC 16 cases/ADC 12 cases; stage III 12 cases/stage IV 16 cases 28 (20/8);
CIV: 14;
IIV: 14
CIV: Endostar by infusion pump (225 mg, 2 ml/h) from day 1 to 15, combined with NP chemotherapy (vinorelbine and cisplatin);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 3–4 h/d) from day 1 to 14, combined with NP chemotherapy (vinorelbine and cisplatin)
Efficacy: ORR, DCR; safety: leukopenia, neutropenia, anemia, nausea & vomiting, cardiovascular toxicity
Tang et al. NRCT 26–78 years old; all patients with advanced NSCLC 54 (34/20);
CIV: 28;
IIV: 26
CIV: Endostar by intravenous infusion (7.5 mg/m2, 4 h) on day 1, Endostar by infusion pump (195 mg, 1.8 ml/h) from day 2 to 8, combined with GP chemotherapy (gemcitabine and cisplatin);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin)
Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, nausea & vomiting, alopecia
Meng NRCT 25–70 years old (mean: 57); all patients with stage IV NSCLC 40 (28/12);
CIV: 20 (13/7);
IIV: 20 (15/5)
CIV: Endostar by intravenous infusion (7.5 mg/m2, 4 h) on day 1, Endostar by infusion pump (195 mg, 1.8 ml/h) from day 2 to 8, combined with GP chemotherapy (gemcitabine and cisplatin);
IIV: Endostar by intravenous infusion (7.5 mg/m2/d, 4 h/d) from day 1 to 14, combined with GP chemotherapy (gemcitabine and cisplatin)
Efficacy: ORR, DCR; safety: cardiovascular toxicity, myelosuppression, gastrointestinal reaction
  1. a The treatment cycle of all included studies was 21 days. In all studies patients were treated for at least two cycles, except for one study [21] in which patients were treated for at least one cycle